N-3 fatty acids for improvement in Respiratory Outcomes - the N3RO Trial

This dataset includes 1273 very preterm infants born at less than 29 weeks of gestation recruited into the N3RO trial. Infants were randomised to receive an enteral DHA or control emulsion from the first 3 days of enteral feeds until 36 weeks postmenstrual age or discharge home, whichever occurred first. Baseline clinical and sociodemographic characteristics of the infants and their families were collected, along with blood spot samples for fatty acid analysis at baseline and 36 weeks postmenstrual age. The primary outcome was bronchopulmonary dysplasia, as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks postmenstrual age. Also available are data on secondary clinical outcomes collected during the neonatal hospitalisation. File type is .PDF.

本数据集纳入了1273名胎龄小于29周的极早早产儿，所有受试者均参与了N3RO临床试验。受试者于肠内喂养启动后的前3天起被随机分配接受肠内二十二碳六烯酸（DHA）乳剂或对照乳剂，直至达到校正胎龄36周或出院，以二者中先发生者为准。研究人员收集了患儿及其家庭的基线临床与社会人口学特征数据，同时采集了基线及校正胎龄36周时的血斑样本用于脂肪酸分析。本研究的主要结局为支气管肺发育不良（bronchopulmonary dysplasia），以校正胎龄36周时需补充氧气和/或辅助通气的情况作为评估标准。此外，数据集还包含新生儿住院期间收集的次要临床结局数据。本数据集文件格式为.PDF。

搜集汇总

背景与挑战

背景概述

该数据集是N3RO临床试验的数据集，包含1273名妊娠不足29周的极早产儿，旨在研究肠内DHA补充对支气管肺发育不良等呼吸结局的影响。数据涵盖基线特征、脂肪酸分析以及主要和次要临床结局，以PDF格式提供，由南澳大利亚健康与医学研究所于2023年发布。